The Technical Analyst
China Pharma Holdings Inc [CPHI]
Exchange: AMEX Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
China Pharma Holdings Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.53% $0.304
America/New_York / 25 apr 2024 @ 11:31
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.50 mill |
| EPS: | -0.910 |
| P/E: | -0.330 |
| Earnings Date: | May 16, 2024 |
| SharesOutstanding: | 14.82 mill |
| Avg Daily Volume: | 0.470 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.330 | sector: PE -4.07 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.330 | industry: PE -1.290 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.266 - 0.346 ( +/- 13.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-28 | Liu Tao (chengdu) | Sell | 0 | Common Stock |
| 2023-09-29 | Li Zhilin | Buy | 13 757 063 | Common Stock |
| 2022-12-30 | Deng Ke | Sell | 0 | Common Stock |
| 2021-09-09 | Li Zhilin | Buy | 1 760 000 | Common Stock |
| 2020-12-23 | Li Zhilin | Buy | 2 000 000 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 33 transactions |
| Buy: 32 776 034 | Sell: 18 065 779 |
Forecast:
13:10 - $0.311
Live Trading Signals (every 1 min)
Forecast
1: 11:40 - $0.305
Forecast 2: 12:30 - $0.308
Forecast 3: 13:10 - $0.311
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.304 (-3.53% ) |
| Volume | 0.102 mill |
| Avg. Vol. | 0.470 mill |
| % of Avg. Vol | 21.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CPHI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CPHI
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
Latest Press Releases
2024-02-23 16:05:00 - Press Release
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
Haikou, china , feb. 23, 2024 /prnewswire/ -- china pharma holdings inc. ("china pharma" or the "company") (nyse american: cphi) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective wednesday, march 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day. trading in the common stock will continue on the nyse american under the symbol "cphi".
2023-11-29 08:00:00 - Press Release
China Pharma Holdings, Inc. Announced The Completion Of Third Party Testing Of Dry Eye Disease Therapeutic Device
Haikou, china , nov. 29, 2023 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma", or the "company"), an nyse american-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in china, today announced that its dry eye disease (ded) therapeutic device has passed third-party testing and is preparing to apply for market launch to the national medical products administration (nmpa) of china. according to a disclosure by the shanghai public health clinical center on june 6, 2023, an epidemiological survey of ded showed that approximately 344 million patients are suffering from ded worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%.
2023-08-09 08:30:00 - Press Release
China Pharma's Candesartan Hypertension Product Passes The Quality And Efficacy Consistency Evaluation Of Generic Drugs
Haikou, china , aug. 9, 2023 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma," the "company" or "we"), a specialty pharmaceutical company, today announced that its wholly-owned subsidiary hainan helpson medical & biotechnology co., ltd. (hereinafter referred to as "helpson") has received the "drug supplementary application approval notice" for its candesartan tablets by national medical products administration of china (hereinafter referred to as nmpa"), indicating that the company's candesartan tablets have passed the quality and efficacy consistency evaluation of generic drugs.
2021-08-13 16:30:00 - Press Release
China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results
Haikou, china, aug. 13, 2021 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma," the "company" or "we"), an nyse american-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in china, today announced the financial results for the quarter ended june 30, 2021. revenue decreased by 35.9% to $2.4 million for the three months ended june 30, 2021, as compared to $3.8 million for the three months ended june 30, 2020.
2021-08-05 09:00:00 - Press Release
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests And The Company Plans To Apply For Nmpa Approval
Haikou, china , aug. 5, 2021 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma," the "company" or "we"), a specialty pharmaceutical company, today announced that its candesartan hypertension product passed key bioequivalence tests. the company plans to use the results of the key benchmark tests of consistency evaluation to apply for the national medical products administration's (nmpa) approval.
Latest News
2022-12-06 13:02:19 - Pulse2
China Pharma (CPHI) Stock: Why It Has Been Volatile This Week
2022-06-09 16:15:47 - PennyStocks
3 Penny Stocks, Are They Worth Buying Right Now?
Check these three penny stocks out for your watchlist right now The post 3 Penny Stocks, Are They Worth Buying Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-08-23 13:09:35 - InvestorPlace
7 Discord Stocks Investors Are Pumping Higher
Move over Reddit! These popular Discord stocks just might give fans of speculative opportunities the swing trades they're looking for.
2021-08-13 16:30:00 - PRNewsWire
China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results
HAIKOU, China, Aug. 13, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended June 30, 2021. Revenue decreased by 35.9% to $2.4 million for the three months ended June 30, 2021, as compared to $3.8 million for the three months ended June 30, 2020.
2021-08-05 09:00:00 - PRNewsWire
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval
HAIKOU, China , Aug. 5, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to apply for the National Medical Products Administration's (NMPA) approval.
2021-06-09 08:00:00 - PRNewsWire
China Pharma to Launch Highly Purified NMN+PQQ Product
HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale test. β-Nicotinamide mononucleotide (NMN) is a derivative of the B-vitamin niacin, which is believed to significantly improve health and wellness.
2021-05-14 16:30:00 - PRNewsWire
China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue
HAIKOU, China, May 14, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2021. Revenue increased by 33.7% to $2.4 million for the three months ended March 31, 2021, as compared to $1.8 million for the three months ended March 31, 2020.
2021-04-19 08:30:00 - PRNewsWire
China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port
HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Relax Market Access" released by the National Development and Reform Commission and the Ministry of Commerce in April. This statement follows the release of the Overall Plan for the Construction of Hainan Free Trade Port in June 2020 and the establishment of the Hainan Boao Lecheng International Medical Tourism Pilot District in 2013, which were both approved by the State Council.
2021-03-29 13:16:07 - InvestorPlace
Top Penny Stocks Today: What to Know About BAYP, SEAC, UPC, CPHI, CYAN Stocks
Shares of several penny stocks are on the rise today as Reddit investors continue to pick out the top ones to take a risk on. The post Top Penny Stocks Today: What to Know About BAYP, SEAC, UPC, CPHI, CYAN Stocks appeared first on InvestorPlace.
2021-03-26 17:00:00 - PRNewsWire
China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results
HAIKOU CITY, China , March 26, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal year ended December 31, 20 20 . Full Year Highlights Revenue was both $10.9 million in fiscal year 2020 and 2019 , respectively ; Gross margin was 1 8.0 % in fiscal year 20 20 , compared to 1 3.6 % in fiscal year 201 9; Loss from operations was $2 .6 million in fiscal year 20 20 compared to $ 2 0.4 million in fiscal year 201 9 , which represented a n improvement of $ 17.8 million; Net loss was $2 ...